Drug Trial Radar · NCT02912949
A Study of Zenocutuzumab (MCLA-128) in Patients With Solid Tumors Harboring an NRG1 Fusion (eNRGy)
Last checked: Nov 20, 2026Latest source record: Apr 29, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
250
Planned (sponsor's estimate)
Start
Jan 2015
Primary completion
Dec 31, 2026
Study completion Dec 31, 2026
Sponsor
- Lead sponsor
- Partner Therapeutics, Inc.Industry
- Sponsor type
- Industry
- First posted
- Sep 23, 2016
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a Phase I/II, open-label, multi-center, multi-national, dose escalation, single agent study to assess the safety, tolerability, PK, PD, immunogenicity and anti-tumor activity of zenocutuzumab (MCLA-128) in patients with solid tumors harboring an NRG1 fusion (eNRGy)
Conditions
- Solid Tumours Harboring NRG1 Fusion
- NSCLC Harboring NRG1 Fusion
- Pancreatic Cancer Harboring NRG1 Fusion
- NRG1 Fusion
Interventions
zenocutuzumab (MCLA-128)Drug
full length IgG1 bispecific antibody targeting HER2 and HER3
Primary outcomes
What the sponsor says the trial is designed to measure.
- Objective overall response rate (ORR) as per local investigator's assessmentTime frame: 36 months
- Duration of response per RECIST v1.1 as per local Investigator's assessment.Time frame: 36 Months
Locations
64 sites in 18 countries. Site status is shown where the registry gives one.
Mayo Clinic
Phoenix, Arizona
The Oncology Institute of Hope and Innovation
Cerritos, California
University of California Irvine
Irvine, California
Stanford University
Palo Alto, California
Sharp Memorial Hospital
San Diego, California
Georgetown University
Washington D.C., District of Columbia
Memorial Cancer Institute
Hollywood, Florida
Cancer Specialists of North Florida
Jacksonville, Florida
Mayo Clinic
Jacksonville, Florida
Emory Winship Cancer Institute
Atlanta, Georgia
Northwest Oncology & Hematology
Rolling Meadows, Illinois
Dana Farber Cancer Center
Boston, Massachusetts
Karmanos Cancer Center
Detroit, Michigan
Mayo Clinic
Rochester, Minnesota
Billings Clinic Cancer Center
Billings, Montana
St. James Healthcare
Butte, Montana
Memorial Sloan Kettering Cancer Center
New York, New York
University of Pennsylvania
Philadelphia, Pennsylvania
Averra Medical Group
Sioux Falls, South Dakota
The University of Texas MD Anderson Cancer Center
Houston, Texas
Huntsman Cancer Institute
Salt Lake City, Utah
Utah Cancer Specialists
Salt Lake City, Utah
Hematology-Oncology Specialist of Fredericksburg
Fredericksburg, Virginia
Virginia Mason Hospital & Seattle Medical Center
Seattle, Washington
Hematology Oncology Associates
Spokane, Washington
Northwest Medical Specialties
Tacoma, Washington
Salzburger Universitatsklinikum
Salzburg, Austria
UZ Leuven
Leuven, Belgium
Princess MargaretCancer Centre
Toronto, Ontario, Canada
Rigshospitalet
Copenhagen, Denmark
Centre Leon Berard
Lyon, France
Hospital Louis Pradel, FR
Lyon, France
Institut Gustave Roussy
Paris, France
Hopital Cochin
Paris, France
Hopital Curie
Paris, France
Asklepios Klinik Altona
Hamburg, Germany
Asklepios Kliniken Hamburg GmbH
Hamburg, Germany
Deutsches Krebsforschungszentrum
Heidelberg, Germany
Shaare Zedek Medical Center
Jerusalem, Israel
Sheba Medical Center
Tel Aviv, Israel
Showing 40 of 64 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.